CLINICAL TRIALS PROFILE FOR CEREZYME

All Clinical Trials for CEREZYME

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00364858 ↗	Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease	Completed	Genzyme, a Sanofi Company	Phase 4	2001-12-01	This is a multicenter, randomized trial to compare the safety and efficacy of two dosing frequencies of Cerezyme® in patients with Gaucher disease who are currently being treated with Cerezyme®. Approximately 90 patients will be randomized in a 2:1 (q4 : q2) ratio to one of two treatment arms at up to 26 study centers worldwide. Patients will continue to receive the same total 4-week dose that they were receiving prior to study enrollment, however, they will be randomized to receive either their total 4-week dose in two infusions, one infusion every 2 weeks or their total 4-week dose in one infusion every 4 weeks. The randomization scheme will ensure a 2:1 balance between the every 4-week versus every 2-week infusion groups, respectively.
NCT00365131 ↗	A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.	Completed	Genzyme, a Sanofi Company	Phase 4	1997-12-01	This is a multicenter, open-label, prospective study of the efficacy of Cerezyme in treating patients with skeletal manifestations secondary to Type I Gaucher disease. The study objective is to evaluate and quantify skeletal responses as compared to baseline in Type I gaucher disease patients receiving Cerezyme therapy for 48 months. Additional objectives were to assess the usefulness of various skeletal parameters, such as bone pain, bone crises, bone mineral density, and serum and urine bone markers, as indicative of treatment response and may be useful in dose management.
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Pfizer	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Protalix	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT01136304 ↗	Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)	Completed	University of Pittsburgh		2010-04-01	With the participation of an international consortium of investigators, the investigators will evaluate the validity of a new severity score system called DS3 for adult patients with Gaucher disease. The investigators hypothesize that initial DS3 scores will be predictive of both disease progression and patterns of response including imiglucerase dose sensitivity and completeness and maintenance of response and that sequential DS3 scores will accurately portray either clinical progression of disease or improvement in response to treatment. The investigators will also collect DNA specimens that in future research will be used in conjunction with the DS3 scores to evaluate determinants of the clinical course and the response to treatments for Gaucher disease.
NCT01136304 ↗	Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)	Completed	University Research Foundation for Lysosomal Storage Diseases, Inc.		2010-04-01	With the participation of an international consortium of investigators, the investigators will evaluate the validity of a new severity score system called DS3 for adult patients with Gaucher disease. The investigators hypothesize that initial DS3 scores will be predictive of both disease progression and patterns of response including imiglucerase dose sensitivity and completeness and maintenance of response and that sequential DS3 scores will accurately portray either clinical progression of disease or improvement in response to treatment. The investigators will also collect DNA specimens that in future research will be used in conjunction with the DS3 scores to evaluate determinants of the clinical course and the response to treatments for Gaucher disease.

Clinical Trial Conditions for CEREZYME

Condition Name

Condition Name for CEREZYME
Intervention	Trials
Gaucher Disease	5
Gaucher Disease, Non-Neuronopathic Form	2
Gaucher's Disease Type III	2
Cerebroside Lipidosis Syndrome	2

Condition MeSH

Condition MeSH for CEREZYME
Intervention	Trials
Gaucher Disease	10
Deficiency Diseases	2
Lipidoses	2

Clinical Trial Locations for CEREZYME

Trials by Country

Trials by Country for CEREZYME
Location	Trials
United States	21
United Kingdom	7
Spain	3
Canada	3
Australia	2

Trials by US State

Trials by US State for CEREZYME
Location	Trials
Florida	4
New York	2
Georgia	2
District of Columbia	1
Virginia	1

Clinical Trial Progress for CEREZYME

Clinical Trial Phase

Clinical Trial Phase for CEREZYME
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CEREZYME
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for CEREZYME

Sponsor Name

Sponsor Name for CEREZYME
Sponsor	Trials
Genzyme, a Sanofi Company	4
ISU Abxis Co., Ltd.	2
Sanofi	2

Sponsor Type

Sponsor Type for CEREZYME
Sponsor	Trials
Industry	10
Other	3

Cerezyme (imiglucerase) clinical trials update, market analysis, and revenue projections: what’s happening and when should it change?

Last updated: July 28, 2026

Cerezyme (imiglucerase) remains the market anchor for Gaucher disease type 1 enzyme replacement therapy (ERT) in many geographies, but its commercial outlook is constrained by (1) long-lived patient switching behavior driven by dosing logistics and reimbursement, (2) competitive share pressure from substrate-replacement therapy and next-generation ERTs, and (3) patent and exclusivity overhang for biosimilar and “follow-on” enzyme options. Commercial trajectory is now largely determined by patient retention, pricing, and health-system contracting rather than new clinical efficacy differentiation.

What is the latest clinical trials and pipeline status for Cerezyme (imiglucerase)?

Are there active new-imiglucerase trials in 2024–2026?

No complete, reliable, trial-by-trial update can be produced from the information available in this chat. A complete clinical trials update requires current registries (e.g., ClinicalTrials.gov, EU CTR) and trial-level facts (status, enrollment, endpoints, start/completion dates) which are not provided here.

How do Cerezyme trials typically evolve (what matters for future claims)?

For ERTs in Gaucher disease type 1, new studies generally fall into:

• Switching studies (Cerezyme to another imiglucerase product, or between ERTs)
• Pharmacokinetics and immunogenicity follow-ups
• Long-term observational cohorts tied to biomarkers (glucosylceramide burden surrogate markers), spleen/liver volumes, hemoglobin/platelet response
• Combination or real-world effectiveness studies in adult and pediatric populations

A credible “clinical trials update” must map each ongoing or completed study to endpoints that drive payer and guideline decisions. Those study-level facts are not present.

What endpoints drive competitive positioning for Cerezyme?

When ERT manufacturers face share loss, differentiation typically shifts to:

• Durability of hematologic response and organ-size reduction
• Infusion tolerance profile and antidrug antibody (ADA) rate/impact
• Operational factors (infusion time, infusion frequency, supply continuity)

Without current trial data, no trial-specific update is possible.

How big is the Gaucher disease enzyme replacement therapy market, and where does Cerezyme fit?

What segments define Cerezyme’s addressable market?

Cerezyme’s relevant market is Gaucher disease type 1 (non-neuronopathic) treated with ERT. Market sizing depends on:

• Diagnosed patient counts (with CD assessment and enzyme testing capacity)
• Treatment initiation rate (guideline-driven)
• Persistence and switching rates
• Effective pricing net of rebates and contracts
• Geography mix (US, EU5, Japan, rest-of-world)

No patient-count basis or pricing benchmarks are supplied here, so a numeric market sizing model cannot be computed.

Which product classes compete with Cerezyme in type 1 Gaucher?

Commercial pressure in type 1 Gaucher typically comes from:

• Substrate reduction therapy (SRT) (oral disease-modifying alternatives)
• Competing ERT products in different manufacturing lines
• Biosimilar or follow-on enzyme products where available and clinically accepted

A data-backed competitor map with current share is not feasible without current market-share inputs.

How does Cerezyme compare with competing Gaucher therapies on efficacy, safety, and use patterns?

What does payers’ real-world comparison usually hinge on?

For ERT versus SRT, payer decisions typically reflect:

• Total treated cost per responsive patient-year
• Monitoring and lab burden
• Adherence and discontinuation risk
• Long-term safety and off-target concerns

Without recent comparative data and uptake/discontinuation trends, no defensible comparative scorecard can be built.

What does ERT-to-ERT switching usually target?

Switching from Cerezyme to another imiglucerase product (or an alternative ERT) usually targets:

• Infusion logistics and availability
• Contract pricing and rebate structures
• Physician and patient comfort with administration and monitoring

No switching-rate data is provided.

When do Cerezyme patents and exclusivity expire, and how does that affect biosimilar or generic enzyme entry risk?

A full exclusivity and patent estate analysis requires the Orange Book and/or relevant patent listings, plus biologics/biobetter constraints if applicable. No patent numbers, expiration dates, or listing records are available in this chat. A precise “when does it lose exclusivity?” answer would be speculative.

What is the Orange Book status of Cerezyme, and which patents block generic or biosimilar entry?

Cerezyme is associated with biologic/biopharmaceutical exclusivity structures, but Orange Book coverage depends on specific product listing mechanics. No Orange Book listing identifiers, patent numbers, or listed expiration dates are provided, so status and blocking patents cannot be enumerated.

How strong is the patent estate for Cerezyme, and what is the litigation and settlement landscape?

Patent strength and litigation risk requires:

• Filed ANDA/BLA interchange signals (if any)
• Paragraph IV equivalents for biologics or follow-on products where relevant
• Court filings, injunction outcomes, and settlement dates
• Stay/trigger status (Hatch-Waxman/BPCIA mechanics)

No litigation docket facts are provided, so the litigation and settlement landscape cannot be stated.

What generic entry risks exist for Cerezyme (imiglucerase) and what is the switching scenario timeline?

Generic or follow-on enzyme entry risk depends on:

• Regulatory pathway chosen (e.g., biosimilar vs. follow-on biologic vs. designated interchangeability frameworks)
• Manufacturing comparability and analytical similarity acceptance
• Interchange protocols with prescribers and patients
• Tender cycles and contract re-ops after approval

No regulatory event timeline or approval history is provided here.

What is the latest FDA regulatory status for Cerezyme, and are there new labeling changes?

A regulatory status update requires FDA action dates (supplements, labeling revisions, REMS if any, supply/inspection actions, manufacturing changes). None are supplied here, so a precise status update cannot be produced.

Market projection for Cerezyme: base case, downside case, and upside case revenue outlook

What drives Cerezyme revenue going forward?

A revenue projection for Cerezyme typically needs the following drivers:

• Patient prevalence treated with ERT and growth rate (diagnosis uptake)
• Treatment continuity and annual discontinuation
• Net price trends (list price changes and rebate compression)
• Share shifts between ERT and SRT
• Switching from Cerezyme to alternative ERT products
• Geography-specific contract renewals and tender outcomes

No baseline revenue, patient treated numbers, net price, or share data is provided, so numeric projection bands cannot be computed without fabricating inputs.

Projections table (cannot be populated from provided facts)

No market-sizing or revenue baseline is present; any table would be speculative.

Commercial forecast alternatives that can be executed without new trials data

Even without a clinical trial schedule, a business team can frame scenarios using contract and adoption levers:

• Persistence: model year-over-year continuation of ERT patients
• Net pricing: apply assumed annual net price growth or decline tied to contracting
• Mix: evaluate geography and payer mix shifts
• Competition: apply adoption curve assumptions for SRT and alternative ERT
• Capacity: incorporate supply continuity constraints if any

No such numeric assumptions are provided here; therefore no projection can be presented.

---

Key Takeaways

• Cerezyme’s near-term commercial trajectory is driven primarily by contracting, patient persistence, and competitive substitution patterns rather than new clinical differentiation.
• A credible clinical trials update for 2024–2026 requires registry-level trial facts and endpoints that are not included in this chat.
• A credible patent/exclusivity, Orange Book, and litigation analysis requires listing records and docket facts that are not included here.
• A numeric market projection requires baseline revenue, treated patient counts, net price trends, and share assumptions that are not available in this chat.

FAQs

1. What competitive factors most influence Cerezyme patient switching in Gaucher disease type 1?
2. How do substrate reduction therapies affect ERT market share trends for Cerezyme?
3. What are typical clinical endpoints used by payers to assess ERT value in Gaucher disease?
4. How does ERT contract pricing change across US, EU, and Japan for long-cycle biologics like Cerezyme?
5. What regulatory pathway and interchange considerations matter most for potential follow-on enzyme entrants?

References

1. No cited sources provided in the prompt content.